Centogene N.V. Common Shares - CNTG STOCK NEWS

Centogene N.V. (Nasdaq: CNTG) has launched NEW CentoGenome®, an advanced Next Generation Sequencing (NGS)-based assay aimed at improving diagnostic accuracy for rare and neurodegenerative diseases. This new test offers comprehensive whole genome sequencing, capable of detecting nearly all disease-causing variants in a single assay. By implementing a PCR-free approach, the test reduces bias and increases sequencing quality, especially in complex genetic regions. The CentoGenome assay includes integrated support for lifelong diagnostic confirmation. Centogene's Biodatabank, housing data from approximately 700,000 patients across over 120 countries, reinforces the assay's effectiveness. These developments are anticipated to enhance the capabilities of healthcare professionals in diagnosing and identifying treatment options more swiftly.

Centogene N.V. (Nasdaq: CNTG) has announced an extension of its partnership with Takeda to enhance global diagnostics for Lysosomal Storage Disorders (LSDs), effective from April 11, 2023. The renewed one-year fee-for-service agreement aims to improve patient access to rapid diagnostics for conditions such as Fabry disease, Gaucher disease, and Hunter syndrome. Centogene's Chief Commercial Officer, Ian Rentsch, emphasized the partnership's role in accelerating diagnosis and increasing access to therapeutics. A key asset is the CENTOGENE Biodatabank, which includes data from approximately 700,000 patients across over 120 countries. This agreement builds on the original collaboration that began in 2015 with Shire Pharmaceuticals, which Takeda acquired in 2019.

Centogene N.V. (Nasdaq: CNTG) has appointed Ian Rentsch as Chief Commercial Officer and General Manager - Pharma, effective March 15, 2023. Rentsch brings over 25 years of global experience in the pharmaceutical and life sciences sectors, previously working with top organizations like IQVIA and AETION. His expertise in clinical development and real-world evidence generation is expected to enhance Centogene's growth strategy. CEO Kim Stratton emphasized Rentsch's strategic thinking and business acumen, highlighting confidence in his ability to drive value creation. Centogene focuses on integrating multiomic technologies to provide solutions for rare and neurodegenerative diseases.

Centogene N.V. (Nasdaq: CNTG) announced its conference schedule for March 2023, with events in Brazil, the U.S., Saudi Arabia, Thailand, and the U.K. The company encourages attendees to arrange one-on-one meetings at these conferences to explore collaboration opportunities.

Key events include:

• Brazilian Congress of Neurogenetics: March 9-11 in São Paulo.
• ACMG Annual Clinical Genetics Meeting: March 14-18 in Salt Lake City.
• World Rare Disease Day Conference: March 15-16 in Medina.
• Gene Therapy Summit: March 20-23 in Boston.
• Asian Congress on Inherited Metabolic Diseases: March 22-24 in Bangkok.
• Pharma USA: March 28-29 in Philadelphia.
• Research & Innovation Meeting: March 29-30 in Hinxton.

Centogene N.V. (Nasdaq: CNTG) announced an expansion of the EFRONT study to enhance understanding of frontotemporal dementia (FTD), a neurodegenerative disease with no FDA-approved treatments. The study aims to enroll over 2,500 genetically tested FTD patients across seven countries, leveraging a network of approximately 30,000 physicians. Participants with specific genetic mutations may join Alector’s Phase 3 INFRONT-3 clinical trial for an investigational treatment. This initiative coincides with Rare Disease Day on February 28, highlighting the urgent need for therapeutic options for FTD patients.

Centogene N.V. (Nasdaq: CNTG) has announced it regained compliance with Nasdaq's minimum bid price requirement, as confirmed by a notification from Nasdaq's Listing Qualifications Department. The company previously faced non-compliance due to its stock trading below $1.00 for 30 consecutive days. Compliance was restored as of February 3, 2023, when the company maintained the required closing bid price. With this development, Centogene is now compliant with all Nasdaq listing standards. Founded in 2006, Centogene focuses on data-driven solutions for rare and neurodegenerative diseases through its comprehensive Biodatabank and collaboration with pharmaceutical partners.

Centogene N.V. (Nasdaq: CNTG) has announced its partnering conference schedule for February 2023, aligning with Rare Disease Day (RDD) on February 28. RDD aims to raise awareness of rare diseases, engaging various stakeholders including physicians and patient organizations. Centogene emphasizes its commitment to the over 350 million rare disease patients globally, participating in events in Boston, Orlando, and Lublin. Key presentations include insights into Niemann-Pick type C1 and Gaucher diseases, featuring expert speakers from the company. The firm invites collaboration opportunities to advance precision medicine and enhance patient outcomes.

Twist Bioscience (TWST) and Centogene (CNTG) have launched three next-generation sequencing target enrichment panels aimed at advancing research and diagnostics for rare diseases and hereditary cancers. These panels enhance the precision of genetic sequencing and are based on data from Centogene's Biodatabank, which includes nearly 700,000 patients. The products include the Twist Alliance CNTG Exome Panel, CNTG Rare Disease Panel, and CNTG Hereditary Oncology Panel. This collaboration is expected to improve diagnostic capabilities worldwide, facilitating earlier disease detection and treatment development.

Centogene N.V. announced an extension of the Rostock International Parkinson's Disease (ROPAD) Study, aimed at enhancing understanding of Parkinson's disease (PD) genetics. Following the testing of over 12,500 participants, the study will expand its recruitment efforts at 48 sites across 10 countries. The study focuses on genetic variations in the LRRK2 gene, with potential eligibility for patients in ongoing therapeutic clinical studies. The collaboration with Denali Therapeutics aims to accelerate drug discovery for PD, which affects over 10 million people globally.